A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
10/2006
10/31/2006	US7129250 Neuroprotective and anti-proliferative compounds
10/31/2006	US7129247 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
10/31/2006	US7129246 N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
10/31/2006	US7129244 Triazolopyrimidines and related analogs as HSP90-inhibitors
10/31/2006	US7129243 Respiratory system disorders; cardiovascular disorders; antidiabetic agents; antiarthritic agents; antiinflammatory agents; immunosuppressants
10/31/2006	US7129242 Such as 4-((4-chlorophenyl)pyrimidin-2-yl)amino)benzamide; for treatment of inflammation/autoimmune conditions
10/31/2006	US7129241 Pyridazine derivatives
10/31/2006	US7129240 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/31/2006	US7129236 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/31/2006	US7129219 enhance humoral and cell-mediated immune responses to vaccine antigens; 2-deoxy-2-amino- beta -D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group
10/31/2006	US7129073 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
10/31/2006	CA2355886C Substituted oximes and hydrazones as neurokinin antagonists
10/31/2006	CA2333405C Spill resistant pharmaceutical compositions
10/31/2006	CA2276455C Phthalazinones
10/31/2006	CA2262906C Novel immunotherapeutic agents and their use in the reduction of cytokine levels
10/31/2006	CA2214670C 2-cyano-3, 5-dihydroxyhex-2-enecarboxamide derivatives
10/31/2006	CA2136953C A method for using lipoprotein associated coagulation inhibitor to treat sepsis
10/26/2006	WO2006113942A2 Method of inhibiting cathepsin activity
10/26/2006	WO2006113769A1 Vanilloid receptor ligands and their use in treatments
10/26/2006	WO2006113682A1 Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
10/26/2006	WO2006113034A1 Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
10/26/2006	WO2006113033A1 Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
10/26/2006	WO2006112744A2 Drug composition with analgesic, anti-inflammatory and decongestive activity
10/26/2006	WO2006112739A1 Novel peptides and methods for the treatment of inflammatory disorders
10/26/2006	WO2006112738A1 Novel peptides and methods for the treatment of inflammatory disorders
10/26/2006	WO2006112331A1 Novel condensed pyrrole derivative
10/26/2006	WO2006111791A1 New anti-inflammatory compounds
10/26/2006	WO2006111355A1 Compositions for the prevention and the treatment of pain comprising phosphatidylethanolamine-binding protein (pebp) derived molecules
10/26/2006	WO2006111085A1 A method, formulation and use thereor with improved oral absorption of drugs or nutrients
10/26/2006	WO2006075255A3 Anti-inflamatory macrolide conjugates
10/26/2006	WO2006075004A3 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
10/26/2006	WO2006074057A3 Pyrimidine derivatives as kinase modulators and method of use
10/26/2006	WO2005113534A3 Cxcr1 and cxcr2 chemokine antagonists
10/26/2006	WO2002101008A3 Intracellular signaling molecules
10/26/2006	WO2002100445A8 Treatment and composition for wound healing
10/26/2006	US20060241179 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
10/26/2006	US20060241171 Novel physiologically active substances
10/26/2006	US20060241155 TNF-alpha production inhibitors
10/26/2006	US20060241132 Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
10/26/2006	US20060241131 Pyrrolo[2,3-d]pyrimidine compounds
10/26/2006	US20060241126 Phospholipase inhibitors perticularly phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2; N-(1-Methylpiperidin-4-yl)-(2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-pyrido[2,3-d]pyrimidin-1-yl)-N-(4-(4-trifluoromethylphenyl)phenyl)methylacetamide; amidation
10/26/2006	US20060241116 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates
10/26/2006	US20060241112 Kinase inhibitors
10/26/2006	US20060241087 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
10/26/2006	US20060241066 Decoy composition for treating and preventing inflammatory disease
10/26/2006	US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity
10/26/2006	US20060240519 Novel receptor nucleic acids and polypeptides
10/26/2006	US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells
10/26/2006	US20060240517 Novel receptor nucleic acids and polypeptides
10/26/2006	US20060240048 Pyridine derivatives as cb2 receptor modulators
10/26/2006	US20060240023 Apoptosis-associated protein and use thereof
10/26/2006	US20060240020 Inhibition of complement activation
10/26/2006	US20060240019 Antagonists of HMG1 for treating inflammatory conditions
10/26/2006	US20060240012 For treating inflammation and immunopathy; rheumatoid arthritis
10/26/2006	US20060240010 Methods of modulating CD200 receptors
10/26/2006	US20060239990 Protein Arginine N-Methyltransferase 2 (PRMT-2)
10/26/2006	US20060239957 Using extract of olive leaves
10/26/2006	US20060239936 Delivery of anti-migraine compounds through an inhalation route
10/26/2006	US20060239926 Specific high-relaxivity compounds
10/26/2006	US20060239546 System for image analysis in a network that is structured with multiple layers and differentially weighted neurons
10/26/2006	US20060239545 System for image analysis in a network that is structured with multiple layers and differentially weighted neurons
10/26/2006	US20060237004 Methods for treating trigeminal neuralgia
10/26/2006	US20060237003 Methods for treating headaches
10/26/2006	DE102005019094A1 New aza-heterocyclic compounds are tyrosine kinase inhibitor useful to prevent and/or treat cancer, tumor growth, tumor angiogenesis, arteriosclerosis, diabetic retinopathy and inflammation diseases
10/26/2006	DE102005018191A1 Substituierte zyklische Harnstoff-Derivate und deren Verwendung zur Herstellung von Arzneimitteln Substituted cyclic urea derivatives and their use for the preparation of medicaments
10/26/2006	DE102005018026A1 New substituted styrol stereoisomers are glucocorticoid receptor ligands useful for the treatment of e.g. inflammatory diseases, lung diseases, rheumatic diseases, autoimmune diseases, joint disorders and gastrointestinal disorders
10/26/2006	CA2604842A1 Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
10/26/2006	CA2599618A1 Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
10/25/2006	EP1715038A1 Antibody targeting osteoclast-associated protein
10/25/2006	EP1714981A2 Method for the identification of antigenic peptides
10/25/2006	EP1714979A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
10/25/2006	EP1714976A1 Amino acid sequences from active principle of musk and their acetic salt, also the preparation and usage
10/25/2006	EP1713818A1 Macrolides with antiinflammatory activity
10/25/2006	EP1713805A1 Kinase inhibitors
10/25/2006	EP1713785A1 Halogenated biaryl heterocyclic compounds and methods of making and using the same
10/25/2006	EP1713781A1 Quinazoline derivatives
10/25/2006	EP1713480A2 The use of quaternary pyridinium salts as vasoprotective agents
10/25/2006	EP1713465A2 Compounds and compositions as lxr modulators
10/25/2006	EP1713439A1 Pharmaceutical preparation for the oral cavity
10/25/2006	EP1654262B1 7-azaindole derivatives as cox2 inhibitors
10/25/2006	EP1509498B1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
10/25/2006	EP1458718B1 Quinolinones as prostaglandin receptor ligands
10/25/2006	EP1430053B1 AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
10/25/2006	EP1383511B1 Calcilytic compounds
10/25/2006	EP1265606B1 Cell adhesion inhibitors
10/25/2006	EP1157006B1 Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
10/25/2006	EP1153302B1 Diagnostics and therapeutics for macular degeneration
10/25/2006	EP1109901B1 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF
10/25/2006	EP1097167B1 Neurotrophic growth factor
10/25/2006	EP0828849B1 High-affinity oligonucleotide ligands to pdgf
10/25/2006	CN1852731A Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
10/25/2006	CN1852709A Macrophage activation inhibitor
10/25/2006	CN1852708A Human beta-defensin secretion promoter
10/25/2006	CN1850264A Safflower preparation for treating wound and new preparing method
10/25/2006	CN1850258A Medicine composition having functions of resisting virus and clearing heat and preparing method
10/25/2006	CN1850241A Dispersible tablet of Vitamin C and Lonicera and Forsythia and preparing method thereof
10/25/2006	CN1850239A Vitamin C and Lonicera and Forsythia capsule
10/25/2006	CN1850238A Medicine composition for treating backbone and joint disease
10/25/2006	CN1850231A Longxuejie granules and its preparing technology
10/25/2006	CN1850221A Medicine composition for treating rheumatoid arthritis and rheumatism

1 ... 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 ... 1272